Independent news, expert interviews, and deep-dive analysis spanning AI in pharma, manufacturing, regulatory affairs, and microbiology — curated for decision-makers across the value chain.
The acquisition fast-tracks a next-generation cell therapy pipeline, signaling renewed momentum in non-viral delivery platforms across the sector.
From the lab bench to the boardroom, Pharma Now tracks the science, systems, and strategy that move the industry forward.
Reporting and analysis across regulation, manufacturing, AI, and the science of quality.
A practical breakdown of the revised Annex 1 expectations and how QC teams are adapting their contamination control strategies.
The deal brings mRNA-LNP know-how in-house, compressing the timeline toward a first-in-class in vivo cell therapy.
From target discovery to trial design, research leaders share how AI copilots are reshaping day-to-day science.
The blood-based biomarker assay gives clinicians a faster read on disease activity in relapsing-remitting MS.
Why the FDA's CSA shift moves the focus from documentation volume to risk-based critical thinking.
A step-by-step guide to building defensible sampling plans and risk-ranked monitoring maps for your cleanrooms.
How to calculate statistically sound alert and action limits across classified zones without overreacting to noise.
On building a science-first quality culture, mentoring next-gen leaders, and the future of Indian pharma manufacturing.
Trusted insights for the global pharma ecosystem — delivered free. Get our weekly briefing on regulatory shifts, AI in pharma, and manufacturing trends, plus early access to every issue of the Pharma Now magazine.
Join 40,000+ pharma professionals. No spam — unsubscribe anytime.